RetroGram relates complex genomic information on HIV-1 resistance to the clinical suitability of anti-retroviral drugs (the main task supported by Arezzo technology). Also generates RetroGram a suitability ranking of all FDA approved drugs based on their expected clinical efficacy for an individual patient.
A unique feature of RetroGram is that it includes the experience and opinions of experts in the algorithm to weigh the effect of specific genotypic changes. The included clinical utility was highlighted in a large multi-centre study in Spain. Investigators concluded in their study that "HIV-1 genotyping interpreted by a software package improves the virological outcome when it is added to the clinical information as a basis for decisions on changing anti-retroviral therapy".
RetroGram is currently being used in more than ten international comparison studies of all available genotype interpretation systems. This decision support systems is available as a stand-alone Windows-based application and in a Web-enabled version.

RetroGram is used by more than 250 clinicians in European, Australian and US centers in resistance management of approximately 2,000 HIV-1 infected patients.

The decision support technology used in the implementation of RetroGramTM is AREZZO, based on PROforma and developed by InferMed Ltd., London. The medical content was developed by Virology Networks RetroGram is jointly owned by Virology Networks and Hoffmann-La Roche